Jennifer Litton

Jennifer Litton at MD Anderson Cancer Center is a leader in the management of hereditary BRCA-associated breast cancer and PARP inhibitor therapy. She has contributed to pivotal trials of olaparib and talazoparib in germline BRCA-mutated metastatic breast cancer, including work defining their role in TNBC specifically. Her translational research addresses mechanisms of PARP inhibitor resistance and strategies to overcome it in BRCA-mutated tumors. She leads neoadjuvant studies integrating PARP inhibitors for early-stage BRCA-associated breast cancer.